PF-Atlas › Clinical Trials › NCT06329401

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

AP01 · Phase 2

Registry ID

NCT06329401

Phase

Phase 2

Status

Recruiting

Drug / intervention

AP01

Sponsor

Avalyn Pharma Inc.

Start

2024-04-03

Enrollment

375

Locations

154

About this trial

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.

View NCT06329401 on ClinicalTrials.gov →

Explore related

All AP01 trials All IPF trials

Related trials

AP01 — NCT06951217

Medical disclaimer. This page summarizes public trial data for NCT06329401 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.